Enovis Corporation (NYSE:ENOV – Get Free Report) Director Angela Lalor purchased 887 shares of Enovis stock in a transaction that occurred on Tuesday, November 10th. The shares were purchased at an average cost of $28.28 per share, with a total value of $25,084.36. Following the transaction, the director directly owned 32,373 shares of the company’s stock, valued at $915,508.44. This represents a 2.82% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.
Enovis Stock Performance
Shares of NYSE:ENOV traded up $0.10 during midday trading on Friday, reaching $27.74. 1,205,392 shares of the company’s stock traded hands, compared to its average volume of 1,879,055. The company has a market cap of $1.60 billion, a price-to-earnings ratio of -3.01 and a beta of 1.31. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.08 and a current ratio of 2.15. Enovis Corporation has a one year low of $16.70 and a one year high of $31.67. The stock has a 50 day moving average of $20.52 and a 200 day moving average of $23.22.
Enovis (NYSE:ENOV – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.88 EPS for the quarter, beating the consensus estimate of $0.77 by $0.11. Enovis had a positive return on equity of 13.23% and a negative net margin of 22.86%. The company had revenue of $558.73 million for the quarter, compared to analysts’ expectations of $557.12 million. During the same period last year, the firm posted $0.75 earnings per share. Enovis’s revenue was up 1.8% compared to the same quarter last year. As a group, equities research analysts anticipate that Enovis Corporation will post 3.15 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the company. IFP Advisors Inc boosted its position in Enovis by 5,590.5% in the second quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock worth $25,000 after purchasing an additional 1,174 shares during the last quarter. Allworth Financial LP bought a new stake in shares of Enovis during the 2nd quarter valued at about $36,000. Integrated Wealth Concepts LLC bought a new stake in shares of Enovis during the 2nd quarter valued at about $39,000. Public Employees Retirement System of Ohio purchased a new stake in shares of Enovis during the 2nd quarter valued at about $48,000. Finally, SBI Securities Co. Ltd. purchased a new stake in shares of Enovis during the 3rd quarter valued at about $55,000. Institutional investors own 98.45% of the company’s stock.
Analyst Ratings Changes
ENOV has been the topic of a number of recent analyst reports. BTIG Research raised their price target on shares of Enovis from $36.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, November 5th. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. BMO Capital Markets set a $27.00 price objective on shares of Enovis in a research report on Tuesday, September 1st. Weiss Ratings upgraded shares of Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, November 2nd. Finally, UBS Group restated a “buy” rating and issued a $44.00 target price on shares of Enovis in a report on Monday, October 5th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $38.62.
Get Our Latest Stock Report on Enovis
Enovis News Roundup
These are some of the ENOV news items that stood out recently:
- Positive Sentiment: Directors Angela S. Lalor and Sharon Wienbar bought a combined 3,531 shares in transactions on November 10 and 11, investing about $100,000. Insider buying can signal confidence, though the purchases are relatively small compared with the company’s overall market value. Lalor SEC filing Wienbar SEC filing
- Neutral Sentiment: Enovis management will present at the Jefferies Global Healthcare Conference on November 17. The announcement may give investors an opportunity to hear updates, but it included no new guidance or business developments. Conference announcement
About Enovis
Enovis is a medical technology company that develops products and solutions for orthopedic care, surgery, recovery and rehabilitation. Its offerings include joint replacement implants, foot and ankle products, surgical instruments, orthopedic braces and supports, and rehabilitation equipment. The company serves healthcare providers and patients in markets around the world. Its products are designed to support treatment across different stages of musculoskeletal care, from surgical intervention to recovery and mobility.
Featured Articles
- Five stocks we like better than Enovis
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Enovis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enovis and related companies with MarketBeat.com's FREE daily email newsletter.
